220 related articles for article (PubMed ID: 26822231)
21. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
[TBL] [Abstract][Full Text] [Related]
22. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
[TBL] [Abstract][Full Text] [Related]
23. [Safety and efficacy of pegylated liposomal Doxorubicin and Carboplatin on platinum-sensitive recurrent epithelial ovarian cancer].
Nishio S; Ushijima K; Shimizu T; Tachibana T; Nasu H; Aiko K; Kawano R; Kurokawa Y; Sumino Y; Yokomine M; Takemoto S; Kamura T
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2539-43. PubMed ID: 24335366
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.
Morotti M; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):707-20. PubMed ID: 21434836
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
Chambers LM; Pendlebury A; Rose PG; Yao M; DeBernardo R
Gynecol Oncol; 2020 Aug; 158(2):309-315. PubMed ID: 32499072
[TBL] [Abstract][Full Text] [Related]
27. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.
Salvatorelli E; De Tursi M; Menna P; Carella C; Massari R; Colasante A; Iacobelli S; Minotti G
Drug Metab Dispos; 2012 Dec; 40(12):2365-73. PubMed ID: 22972909
[TBL] [Abstract][Full Text] [Related]
29. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
30. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
31. The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
Miyahara D; Ueda T; Katsuda T; Maehara M; Fukagawa S; Miyata K; Nam SO; Kondo H; Miyamoto S
Anticancer Res; 2015 Aug; 35(8):4521-5. PubMed ID: 26168496
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma.
Rose PG; Radeva M; Michener CM; Link N; Adbul-Karim F
Int J Gynecol Cancer; 2017 Jun; 27(5):907-911. PubMed ID: 28498259
[TBL] [Abstract][Full Text] [Related]
33. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
[TBL] [Abstract][Full Text] [Related]
34. Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity.
Pease DF; Peterson BA; Gilles S; Hordinsky MK; Bohjanen KA; Skubitz KM
Cancer Chemother Pharmacol; 2019 Jul; 84(1):217-221. PubMed ID: 31041511
[TBL] [Abstract][Full Text] [Related]
35. [Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].
Malkowska-Walczak B; Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2009 Sep; 80(9):682-6. PubMed ID: 19886242
[TBL] [Abstract][Full Text] [Related]
36. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
37. Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.
Blaha M; Martinkova J; Lanska M; Filip S; Malakova J; Kubecek O; Bezouska J; Spacek J
Atheroscler Suppl; 2017 Nov; 30():286-293. PubMed ID: 29096853
[TBL] [Abstract][Full Text] [Related]
38. Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer.
Kubeček O; Martínková J; Chládek J; Bláha M; Maláková J; Hodek M; Špaček J; Filip S
Cancer Chemother Pharmacol; 2020 Feb; 85(2):353-365. PubMed ID: 31728628
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
[TBL] [Abstract][Full Text] [Related]
40. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
Lorusso D; Di Stefano A; Carone V; Fagotti A; Pisconti S; Scambia G
Ann Oncol; 2007 Jul; 18(7):1159-64. PubMed ID: 17229768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
